July 16, 2012
MannKind’s inhalable insulin device Afrezza.
Stories this photo appears in:
HEALTH CARE: Expected FDA approval pumps up shares of MannKind.
Investors breathless over outlook for approval of MannKind’s inhalable insulin. 5
BIOTECH: Al Mann ups stake in MannKind as Afrezza trials continue.
MannKind owner’s equity move gives maker of inhalable insulin product some breathing room